Cargando…
Biotechnology and the transformation of vaccine innovation: The case of the hepatitis B vaccines 1968–2000
The approval, from 1986, of a series of recombinant hepatitis B vaccines was a landmark both in the growth of biotechnology and in the development of the vaccine innovation system. In this paper, we show how the early development of the hepatitis B vaccines was shaped by a political and economic con...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541201/ https://www.ncbi.nlm.nih.gov/pubmed/28511068 http://dx.doi.org/10.1016/j.shpsc.2017.05.004 |
_version_ | 1783254773361803264 |
---|---|
author | Huzair, Farah Sturdy, Steve |
author_facet | Huzair, Farah Sturdy, Steve |
author_sort | Huzair, Farah |
collection | PubMed |
description | The approval, from 1986, of a series of recombinant hepatitis B vaccines was a landmark both in the growth of biotechnology and in the development of the vaccine innovation system. In this paper, we show how the early development of the hepatitis B vaccines was shaped by a political and economic context that newly favoured commercialisation of academic research, including the appropriation and management of intellectual property; we elucidate the contingent interests and motivations that led new biotechnology companies and established pharmaceutical businesses to invest in developing recombinant vaccines specifically against hepatitis B; and we show how these and other factors combined to make those vaccines an unexpected commercial success. Broadening the scope of our analysis to include not just North America and Europe but also low- and middle-income countries, we show how the development of the hepatitis B vaccines facilitated the emergence of a two-tier innovation system structured by tensions between the demands for commercial profitability on the one hand, and the expectation of public health benefit for low- and middle-income countries on the other. |
format | Online Article Text |
id | pubmed-5541201 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-55412012017-08-09 Biotechnology and the transformation of vaccine innovation: The case of the hepatitis B vaccines 1968–2000 Huzair, Farah Sturdy, Steve Stud Hist Philos Biol Biomed Sci Article The approval, from 1986, of a series of recombinant hepatitis B vaccines was a landmark both in the growth of biotechnology and in the development of the vaccine innovation system. In this paper, we show how the early development of the hepatitis B vaccines was shaped by a political and economic context that newly favoured commercialisation of academic research, including the appropriation and management of intellectual property; we elucidate the contingent interests and motivations that led new biotechnology companies and established pharmaceutical businesses to invest in developing recombinant vaccines specifically against hepatitis B; and we show how these and other factors combined to make those vaccines an unexpected commercial success. Broadening the scope of our analysis to include not just North America and Europe but also low- and middle-income countries, we show how the development of the hepatitis B vaccines facilitated the emergence of a two-tier innovation system structured by tensions between the demands for commercial profitability on the one hand, and the expectation of public health benefit for low- and middle-income countries on the other. Elsevier 2017-08 /pmc/articles/PMC5541201/ /pubmed/28511068 http://dx.doi.org/10.1016/j.shpsc.2017.05.004 Text en © 2017 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Huzair, Farah Sturdy, Steve Biotechnology and the transformation of vaccine innovation: The case of the hepatitis B vaccines 1968–2000 |
title | Biotechnology and the transformation of vaccine innovation: The case of the hepatitis B vaccines 1968–2000 |
title_full | Biotechnology and the transformation of vaccine innovation: The case of the hepatitis B vaccines 1968–2000 |
title_fullStr | Biotechnology and the transformation of vaccine innovation: The case of the hepatitis B vaccines 1968–2000 |
title_full_unstemmed | Biotechnology and the transformation of vaccine innovation: The case of the hepatitis B vaccines 1968–2000 |
title_short | Biotechnology and the transformation of vaccine innovation: The case of the hepatitis B vaccines 1968–2000 |
title_sort | biotechnology and the transformation of vaccine innovation: the case of the hepatitis b vaccines 1968–2000 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541201/ https://www.ncbi.nlm.nih.gov/pubmed/28511068 http://dx.doi.org/10.1016/j.shpsc.2017.05.004 |
work_keys_str_mv | AT huzairfarah biotechnologyandthetransformationofvaccineinnovationthecaseofthehepatitisbvaccines19682000 AT sturdysteve biotechnologyandthetransformationofvaccineinnovationthecaseofthehepatitisbvaccines19682000 |